Aurinia Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>AP</div>
AUPH -- USA Stock  

USD 13.98  0.28  2.04%

While some of us are excited about healthcare space, it makes sense to concentrate on Aurinia Pharmaceuticals in greater detail to make a better assessment of its actual value. We are going to cover the possibilities of making Aurinia Pharmaceuticals into your portfolio. Is the entity valuation justified? Here I will cover 2020 perspective on the current valuation of the stock to give you a better outlook on taking a possible position in this stock.
Published over a week ago
View all stories for Aurinia Pharmaceuticals | View All Stories
Is Aurinia Pharmaceuticals well positioned for December economic uncertainties?
This firm currently holds 6.2 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest Aurinia Pharmaceuticals is not taking enough advantage from borrowing. Aurinia Pharmaceuticals is UNDERVALUED at 15.55 per share with modest projections ahead. About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.37. Aurinia Pharmaceuticals had not issued any dividends in recent years. The entity had 1:50 split on the 23rd of October 2013.
We determine the current worth of Aurinia Pharmaceuticals using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Aurinia Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Aurinia Pharmaceuticals's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Aurinia Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aurinia Pharmaceuticals. We calculate exposure to Aurinia Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Aurinia Pharmaceuticals's related companies.

Aurinia Pharmaceuticals Investment Alerts

Aurinia investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Aurinia Pharmaceuticals performance across your portfolios.Please check all investment alerts for Aurinia

Aurinia Pharmaceuticals Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Aurinia value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aurinia Pharmaceuticals competition to find correlations between indicators driving the intrinsic value of Aurinia.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Aurinia Pharmaceuticals, but it might be worth checking our own buy vs. sell analysis

Breaking it down a bit more

The company reported the previous year's revenue of 318 K. Net Loss for the year was (141.58 M) with loss before overhead, payroll, taxes, and interest of (52.55 M).

Margins Breakdown

Aurinia profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Aurinia Pharmaceuticals itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Aurinia Pharmaceuticals profit margins.
EBITDA Margin(67.01)
Gross Margin1.17
Profit Margin(73.14)


Aurinia Pharmaceuticals Average Assets is increasing over the last 8 years. Moreover, Aurinia Pharmaceuticals Earnings before Tax is decreasing over the last 8 years.

Another 3 percent rise for Aurinia Pharmaceuticals

Treynor ratio is down to 0.15. It may hint to a possible volatility drop. As of the 14th of November 2020, Aurinia Pharmaceuticals shows the mean deviation of 1.93, and Risk Adjusted Performance of (0.038405). Aurinia Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Aurinia Pharmaceuticals, which can be compared to its rivals. Please confirm Aurinia Pharmaceuticals treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Aurinia Pharmaceuticals is priced correctly, providing market reflects its regular price of 13.4 per share. Given that Aurinia Pharmaceuticals has jensen alpha of (0.047825), we suggest you to validate Aurinia Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Our Conclusion on Aurinia Pharmaceuticals

While some other entities in the biotechnology industry are either recovering or due for a correction, Aurinia may not be as strong as the others in terms of longer-term growth potentials. To conclude, as of the 14th of November 2020, our analysis shows that Aurinia Pharmaceuticals barely shadows the market. The company is undervalued and projects close to average chance of distress for the next 2 years. However, our overall 30 days buy-hold-sell recommendation on the company is Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Aurinia Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com